Novartis to pay $25 million in FCPA case

Switzerland pharmaceutical giant Novartis yesterday reached a $25 million settlement with the Securities and Exchange Commission for violating the books and records and internal accounting controls provisions of the Foreign Corrupt Practices Act concerning its operations in China.

lock iconTHIS IS MEMBERS-ONLY CONTENT. To continue reading, choose one of the options below.